CLINDAMYCIN HYDROCHLORIDE capsule

País: Estados Unidos

Língua: inglês

Origem: NLM (National Library of Medicine)

Ingredientes ativos:

CLINDAMYCIN HYDROCHLORIDE (UNII: T20OQ1YN1W) (CLINDAMYCIN - UNII:3U02EL437C)

Disponível em:

Proficient Rx LP

DCI (Denominação Comum Internacional):

CLINDAMYCIN HYDROCHLORIDE

Composição:

CLINDAMYCIN 300 mg

Via de administração:

ORAL

Tipo de prescrição:

PRESCRIPTION DRUG

Indicações terapêuticas:

Clindamycin hydrochloride capsules, USP are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria.   Clindamycin hydrochloride capsules, USP are also indicated in the treatment of seri‑ous infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the WARNING box, before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin).   Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastroin‑testinal tract);

Resumo do produto:

Clindamycin Hydrochloride Capsules USP, 300 mg are light blue opaque/light blue opaque size ‘0’ hard gelatin capsule filled with white to off-white powder and imprinted with ‘C’ on light blue opaque cap and ‘40’ on light blue opaque body with black ink. Bottles of 21      NDC 63187-127-21 Bottles of 28      NDC 63187-127-28 Bottles of 30      NDC 63187-127-30 Bottles of 40      NDC 63187-127-40

Status de autorização:

Abbreviated New Drug Application

Características técnicas

CLINDAMYCIN HYDROCHLORIDE- CLINDAMYCIN HYDROCHLORIDE CAPSULE
PROFICIENT RX LP
----------
CLINDAMYCIN HYDROCHLORIDE CAPSULES, USP
To reduce the development of drug-resistant bacteria and maintain the
effectiveness of
clindamycin hydrochloride and other antibacterial drugs, clindamycin
hydrochloride
should be used only to treat or prevent infections that are proven or
strongly suspected
to be caused by bacteria.
WARNING
_Clostridium difficile_ associated diarrhea (CDAD) has been reported
with use of
nearly all antibacterial agents, including clindamycin hydrochloride
and may range in
severity from mild diarrhea to fatal colitis. Treatment with
antibacterial agents alters
the normal flora of the colon, leading to overgrowth of _C.
difficile_.
Because clindamycin hydrochloride therapy has been asso‑ciated with
severe colitis
which may end fatally, it should be reserved for serious infec‑tions
where less toxic
antimicrobial agents are inappropriate, as described in the
INDICA‑TIONS AND
USAGE section. It should not be used in patients with nonbacterial
infections such
as most upper respiratory tract infections.
_C. difficile_ produces toxins A and B, which contribute to the
development of CDAD.
Hypertoxin producing strains of _C. difficile_ cause increased
morbidity and mortality,
as these infections can be refractory to antimicrobial therapy and may
require
colectomy. CDAD must be considered in all patients who present with
diarrhea
following antibiotic use. Careful medical history is necessary since
CDAD has been
reported to occur over two months after the administration of
antibacterial agents.
If CDAD is suspected or confirmed, ongoing antibiotic use not directed
against _C._
_difficile _may need to be discontinued. Appropriate fluid and
electrolyte
management, protein supplementation, antibiotic treatment of _C.
difficile_, and
surgical evaluation should be instituted as clinically indicated.
DESCRIPTION
Clindamycin hydrochloride is the hydrated hydrochlo‑ride salt of
clindamycin.
Clindamycin is a semisynt